Heimbruch, Katelyn E.
Fisher, Joseph B.
Stelloh, Cary T.
Phillips, Emily
Reimer, Michael H. Jr.
Wargolet, Adam J.
Meyer, Alison E.
Pulakanti, Kirthi
Viny, Aaron D.
Loppnow, Jessica J.
Levine, Ross L.
Pulikkan, John Anto
Zhu, Nan
Rao, Sridhar
Funding for this research was provided by:
National Institutes of Health (CA204231, CA10011332, CA00874)
Edward P. Evans Foundation
Article History
Received: 10 March 2020
Accepted: 18 March 2021
First Online: 31 March 2021
Competing interests
: RLL is on the Supervisory board of Qiagen, is on the SAB of Loxo (until 2019), Imago, Mana, Auron, C4 Therapeutics and Isoplexis which include equity interest. He receives research support from and consulted for Celgene and Roche and consults for Incyte, Lilly, Janssen, Astellas, Morphosys, Novartis. He receives research support from Prelude. He has received honoraria from Astra Zeneca, Roche, Lilly and Amgen for invited lectures and from Gilead for grant reviews. None of these conflicts were considered relevant by RLL. No other conflicts of interests were reported by other authors.